A Double-blind, Placebo-controlled, Randomized, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Bms-512148 in Diabetic Subjects.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 06 Jan 2011 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.
- 13 Sep 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History